

Research Article

[Withdrawn] Hydralazine Inhibits Cysteamine Dioxygenase to Treat Preeclampsia and Senesce in Glioblastoma

Kyosuke Shishikura¹, Jiasong Li², Yiming Chen³, Nate R. McKnight¹, Katelyn A. Bustin¹, Mahaa Ayub⁴, Zongtao Lin¹, Ren-Ming Hu¹, Kelly Hicks⁵, Xie Wang¹, Donald M. O'Rourke⁶, J. Martin Bollinger, Jr.⁷, Zev A. Binder⁸, William H. Parsons⁹, Kirill A. Martemyanov³, Aimin Liu², Megan L. Matthews¹

1. Department of Chemistry, University of Pennsylvania, United States; 2. Department of Chemistry, The University of Texas at San Antonio, USA; 3. Department of Neuroscience, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, University of Florida, United States; 4. Sidney Kimmel Medical College, Thomas Jefferson University, United States; 5. Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, United States; 6. Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, United States; 7. Department of Chemistry and Biochemistry and Molecular Biology, The Pennsylvania State University, USA; 8. Glioblastoma Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania, United States; 9. Department of Chemistry and Biochemistry, Oberlin College, United States

This manuscript has been withdrawn.

This manuscript has been withdrawn due to a procedural issue regarding the platform's CC BY licensing terms.

Supplementary data: available at <https://doi.org/10.32388/1XPF78>

Declarations

Funding: No specific funding was received for this work.

Potential competing interests: No potential competing interests to declare.